glp 1 drugs australia GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective | Diabetes Therapy Market Overview: GLP-1 Agonists and

If the patient experiences gastrointestinal adverse effects during dose escalation, uptitration can be delayed for an additional week [21]

Lilly has submitted orforglipron for approval in more than 40 countries, with launches expected in each market following regulatory clearance

The Phase 2 trial enrolled participants with obesity and evaluated multiple dose levels over 48 weeks: 1 mg dose: 8.7% average body weight reduction 4 mg dose (escalated from 2 mg): 17.1% average body weight reduction 8 mg dose (escalated from 2 mg): 22.8% average body weight reduction 12 mg dose (escalated from 2 mg): 24.2% average body weight reduction Placebo: 2.1% average body weight reduction Those Phase 2 numbers were striking enough

Per a March 3, 2026 FDA press announcement (FDA.gov press announcement, March 3, 2026), the agency issued warning letters to 30 telehealth companies for making claims that implied sameness with FDA-approved products

In Phase 1 studies, survodutide was generally well tolerated, with no significant safety or tolerability issues observed in either healthy individuals with overweight or obesity [87, 88]

(2020) expanded the anatomical map of GLP-1sensitive regions by showing that Ex4 microinjections into the VTA, NAc core and shell, lateral hypothalamus (LH), and dorsomedial hippocampus (DMHipp) suppressed alcohol intake